Johnson & Johnson subsidiary Janssen has announced the European Commission (EC) has approved Stelara (ustekinumab) for patients with moderately to severely active ulcerative colitis (UC).
Smokers and nonsmokers with ulcerative colitis (UC) have similar outcomes, according to a study published online in Alimentary Pharmacology and Therapeutics.
New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib...